Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02877849
Other study ID # 1606M89781
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 9, 2017
Est. completion date October 31, 2019

Study information

Verified date November 2019
Source University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Due to the relapsing nature of alcoholism, excessive alcohol consumption represents a significant cost to US society ($249 billion in 20101). About 64% of those entering treatment will relapse within one year. New interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. Using resting functional magnetic resonance imaging (fMRI) we have identified brain biomarkers that support long-term abstinence and brain biomarkers that predict relapse. Our data point to specific brain biomarkers that index higher relapse vulnerability at 11 weeks of abstinence. Many individuals, however, have already relapsed by this time. It is unknown whether these biomarkers can be identified earlier during the recovery period. We need to investigate whether this biomarker of relapse vulnerability can be identified during earlier stages of abstinence. Earlier identification of this biomarker will give valuable information for timely targeted interventions (e.g. closer monitoring, longer stay in treatment program, neuromodulation), increasing the chances of maintaining abstinence. The overall objective of this study is to identify biomarkers of relapse during early abstinence (2-3 weeks of abstinence). A secondary objective is to evaluate whether non-imaging measures such as craving6 and executive function7 add value to prediction models. Findings from this proposal will provide insight into the neurobiology of relapse vulnerability that will inform new treatment strategies needed to improve treatment outcome.


Description:

BACKGROUND:

Due to the relapsing nature of alcoholism, excessive alcohol consumption represents a significant cost to US society ($249 billion in 2010). About 64% of those entering treatment will relapse within one year. Development of new and improved treatments that could be personalized to maximize the chance of maintaining abstinence in the first year will require advancement in understanding the behavioral and neural mechanisms underlying vulnerability to relapse during early abstinence. New interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. Using resting functional magnetic resonance imaging (fMRI) we have identified brain biomarkers that support long-term abstinence and brain biomarkers that predict relapse. Our cross-sectional and longitudinal findings provide evidence that higher functional connectivity (FC), particularly between nucleus accumbens (NAcc) and dorsolateral prefrontal cortex (DLPFC) is a potential brain biomarker that supports abstinence. Resting NAcc-DLPFC FC is graded depending on abstinence length, with higher FC in long-term abstinent alcoholics (7 years of abstinence) than controls and intermediate FC in short-term abstinent alcoholics (11 weeks of abstinence). Further, lower NAcc-DLPFC FC at 11-weeks of abstinence can be a predictor of subsequent relapse (with 74% accuracy). Our data point to specific brain biomarkers that index higher relapse vulnerability at 11 weeks of abstinence. Many individuals, however, have already relapsed by this time and were not included in the studies above. It is unknown whether these biomarkers can be identified earlier during the recovery period. We need to investigate whether this biomarker of relapse vulnerability can be identified during earlier stages of abstinence. Earlier identification of this biomarker will give valuable information for timely targeted interventions (e.g. closer monitoring, longer stay in treatment program, neuromodulation), increasing the chances of maintaining abstinence.

PURPOSE OF THE STUDY:

Our long-term goal is to use identified brain and behavioral biomarkers to facilitate the development of new, personalized treatments that will support enduring abstinence in addiction. The overall objective of this study is to identify biomarkers of relapse during early abstinence (2-3 weeks of abstinence). A secondary objective is to evaluate whether non-imaging measures such as craving and executive function add value to prediction models. Findings from this study will provide insight into the neurobiology of relapse vulnerability that will inform new treatment strategies needed to improve treatment outcome.

SPECIFIC AIMS:

SA 1: To evaluate prediction accuracy of FC measures in individuals with alcohol use disorder (AUD) during early (2-3 weeks) abstinence. To evaluate whether non-imaging measures (e.g. craving, executive function) add value to FC prediction models we will test prediction models using (i) only imaging variables (FC during task and rest fMRI), (ii) only non-imaging variables, and (iii) a combination of imaging and non-imaging variables as predictors of time to relapse. Hypothesis: Based on compensatory mechanisms hypothesis, we expect that subsequent abstainers will have stronger NAcc-DLPFC FC when compared to subsequent relapsers and controls. Pilot data suggests that a combination of imaging and non-imaging variables will have high prediction accuracy. SA 2. To expand our examination of NAcc-DLPFC FC beyond resting state we will use the Reversal Learning (RL) task, which involves executive functioning and reward processing. Hypothesis: Pilot data suggests that subsequent abstainers will show higher task-related NAcc FC than relapsers and controls. Exploratory Aim: We will explore whether the strength of resting NAcc-DLPFC FC changes after performing the RL task. We will collect rest fMRI data before and after RL task performance in the scanner. Hypothesis: Based on previous findings of increased task-evoked activity in these regions, we hypothesize that patients will show increased resting NAcc-DLPFC FC after performing the RL task.

SIGNIFICANCE:

Addiction treatment outcomes are poor. Alcohol use disorder (AUD) in the U.S. remains an important public health problem with an estimated total annual cost to society of $249.5 billion. The chronic and relapsing nature of AUD is a major obstacle to successful recovery. We lack tools to subtype in alcohol use disorder (AUD). Subtyping in clinical populations can be an effective approach to model targeted interventions. For example, targeted treatment for breast cancer patients based on individual tumor estrogen receptor typing (biomarker) has improved outcomes from a 25 to 77% survival rate; there has not been a similar improvement in outcome for AUD treatment. We need to identify biomarkers in AUD that predict relapse and guide the development and selection of treatment based on subtypes to increase the chances of achieving long-term abstinence.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date October 31, 2019
Est. primary completion date October 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Alcohol Use Disorder

INCLUSION CRITERIA:

- Age 18-60

- Ability to provide written consent and comply with study procedures

- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for Alcohol Use Disorder

- May have current comorbid drug use, but primary substance use disorder diagnosis needs to be based on alcohol use

- Must be enrolled in Lodging Plus (Fairview Riverside) treatment program

- Must have the intention to remain in program until the end of the study

EXCLUSION CRITERIA:

- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness>30 min, HIV)

- Any MRI scanning contraindications (i.e., metal implants, pacemakers, etc.)

- DSM-V criteria for psychiatric disorder, may have a lifetime but not current diagnosis of depression

- Primary current substance use disorder diagnosis on a substance other than alcohol except for caffeine or nicotine

- Clinical evidence for Wernicke-Korsakoff syndrome

Healthy controls

INCLUSION CRITERIA:

- Age 18-60

- Ability to provide written consent and comply with study procedures

EXCLUSION CRITERIA:

- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness>30 min, HIV)

- Any MRI scanning contraindications (i.e., metal implants, pacemakers, etc.)

- DSM-V criteria for psychiatric disorder, may have a lifetime but not current diagnosis of depression

- Primary current substance use disorder diagnosis on any substance such as alcohol, stimulant, opioids, etc. except for caffeine or nicotine

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRI: Brain Imaging data collection
This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain connectivity measures at baseline Brain imaging data will be collected using a 3T MRI scanner from both groups 2 years
Secondary Follow-up abstinence status Subjects will be called back for follow-up brain imaging data collection, Timeline Follow-back to measure alcohol use, and relapse (abstinence vs relapse) status 6 months after baseline assessments
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A